Clinical trials: Lenvatinib Treatment
Hepatocellulcar Carcinoma
Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line
Although immunotherapy-based therapies (including targeted-immunotherapy or dual-immunotherapy protocols) have become the first-line standard treatment for advanced hepatocellular carcinoma (HCC), there remains a lack of…
- Trial name
- NCT07501351
- Testing
- Intensified Therapy, Conversion Therapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Resectable
A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
In order to improve the R0 resection rate, reduce distant metastasis, and lower postoperative recurrence, there is a growing exploration of surgical treatments for hepatocellular carcinoma (HCC), including preoperative…
- Trial name
- NCT06003673
- Testing
- neoadjuvant therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Carcinoma, Hepatocellular
A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC
The primary objective of this study is to evaluate the safety of lenvatinib in HCC.
- Trial name
- NCT04297254
- Testing
- Lenvatinib
- Where
- 10 sites in India
- Volunteers
- 50 people
- Sponsor
- Eisai Pharmaceuticals India Pvt. Ltd
Hepatocellular Carcinoma
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma…
- Trial name
- CheckMate 9DW (NCT04039607)
- Testing
- Nivolumab, Ipilimumab, Sorafenib
- Where
- 210 sites in United States, Argentina and 24 more
- Volunteers
- 732 people
- Sponsor
- Bristol-Myers Squibb
RCC, Renal Cell Cancer
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
The primary objective is to evaluate the improvement in Objective Response Rate (ORR) achieved with Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) in combination with Lenvatinib or…
- Trial name
- NCT07277972
- Testing
- Iparomlimab and Tuvonralimab Injection in combination with Lenvatinib or Axitinib
- Volunteers
- 36 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Melanoma, Uveal
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
The purpose of this study is to evaluate the efficacy of lenvatinib and pembrolizumab to treat metastatic uveal melanoma.
- Trial name
- NCT05308901
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services
Anaplastic Thyroid Cancer
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer.
- Trial name
- NCT06374602
- Testing
- Pembrolizumab + Lenvatinib
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Saint Petersburg State University, Russia
Metastatic Thymic Carcinoma, Thymoma Type B3
Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents
This is a multicentric, open-label, single arm phase II study to evaluate the efficacy and safety of the combination of pembrolizumab and lenvatinib in pre-treated thymic carcinoma patients who have progressed after at least one…
- Trial name
- PECATI (NCT04710628)
- Testing
- Pembrolizumab, Lenvatinib 10 mg
- Where
- 13 sites in France, Italy and 1 more
- Volunteers
- 43 people
- Sponsor
- MedSIR
Endometrial Neoplasms
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer.
- Trial name
- NCT03517449
- Testing
- Pembrolizumab, Lenvatinib, Paclitaxel
- Where
- 169 sites in United States, Argentina and 19 more
- Volunteers
- 827 people
- Sponsor
- Eisai Inc.
Advanced Biliary Tract Cancer
Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment
To evaluate the following items in patients with advanced cholangiocarcinoma receiving lenvatinib plus paclitaxel treatment, Primary endpoint: Overall response rate (ORR) by RECIST 1.1 Secondary endpoints Progression-free…
- Trial name
- LenPac (NCT05170438)
- Testing
- Lenvatinib Pill,Paclitaxel
- Where
- 8 sites in Taiwan
- Volunteers
- 51 people
- Sponsor
- National Health Research Institutes, Taiwan
Endometrial Neoplasms
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma.
- Trial name
- LEAP-001 (NCT04865289)
- Testing
- Lenvatinib, Pembrolizumab, Paclitaxel
- Where
- 22 sites in China
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Hepatocellular Carcinoma (HCC)
Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC
This is a prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to observe, compare and evaluate the efficacy and safety of Toripalimab combined with Lenvatinib versus…
- Trial name
- NCT04523493
- Testing
- Toripalimab combined with Lenvatinib
- Where
- 22 sites in China, Italy and 3 more
- Volunteers
- 530 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Hepatocellular Carcinoma (HCC)
Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
Advanced hepatocellular carcinoma (HCC) remains a major therapeutic challenge. Although targeted therapy combined with immune checkpoint inhibitors has improved clinical outcomes, the objective response rate and conversion…
- Trial name
- NCT07832006
- Testing
- Irreversible Electroporation, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shunda Du
Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Biliary tract carcinoma (BTC) is a highly aggressive malignancy with rising incidence worldwide. Most patients present at an advanced stage and have a dismal prognosis.
- Trial name
- NCT07530445
- Testing
- Drug: QL1706 5mg/kg, iv drip,d1,Q3W; Albumin-Bound Paclitaxel 125mg/m2, iv drip, d1、d8, Q3W; Lenvatinib 8mg, po, QD
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Clinical Study on the efficacy and safety of HAIC（GEMOX）and Lenvatinib combined with Adebrelimab neoadjuvant therapy for resectable Intrahepatic Cholangiocarcinoma with high-risk recurrence factors.
- Trial name
- NCT06208462
- Testing
- Adebrelimab, Lenvatinib, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric (Stomach) Cancer
Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer
This trial is a prospective, open, randomized, phase II clinical study. It compares the current first-line treatment for advanced gastric cancer in phase II clinical trials, with the best efficacy being the combination of…
- Trial name
- FDZL-GC003 (NCT06748508)
- Testing
- Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib
- Where
- 2 sites in China
- Volunteers
- 141 people
- Sponsor
- Fudan University
Cholangiocarcinoma, Intrahepatic
Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma
We aim to explore the effects and safety of GC (Cisplatin and gemcitabine) chemotherapy combined with Lenvatinib as first-line therapy in advanced or unresectable intrahepatic cholangiocarcinoma
- Trial name
- NCT04527679
- Testing
- GC combined Lenvatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced HCC
Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC
The ORR of the lenvatinib combination (lenvatinib combined with PD-1 inhibitor) was largely similar to that of the "A+T" combination (bevacizumab and atelelizumab).
- Trial name
- NCT05831969
- Testing
- Lenalidomide
- Volunteers
- 23 people
- Sponsor
- Shenyang Tenth People's Hospital
Resectable Clear Cell Carcinoma of the Kidney
Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma.
This study is a single-arm, single-center, phase II clinical study. The main purpose is to evaluate the perioperative efficacy and safety of cardenilimab combined with lenvatinib in patients with resectable clear cell renal cell…
- Trial name
- NCT06574412
- Testing
- cardonilizumab combined with renvastinib
- Volunteers
- 30 people
- Sponsor
- The First Hospital of Jilin University
Hepatocellular Carcinoma
Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC
This study is a single-arm, open-label trial to clarify the safety and efficacy of the combined treatment of lenvatinib and VIC-1911 in patients with advanced liver cancer.
- Trial name
- NCT06519721
- Testing
- Lenvatinib Combined with VIC-1911
- Where
- China
- Volunteers
- 12 people
- Sponsor
- RenJi Hospital